Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver

Positive

AI Analysis

Summary

Evonik is investing over 150 million CAD to establish a new GMP manufacturing facility in Vancouver for lipid nanoparticle development and clinical drug product manufacturing, supported by up to 68 million CAD in external funding.

Importance:5/10

Sentiment:

0.60

manufacturinglipid nanoparticlesLNPGMP facilitydrug deliverycapacity expansionVancouver

Read the original article

Published by PR Newswire Pharma on August 27, 2026 7:17 PM

Read Original